Patent: 9,907,849
✉ Email this page to a colleague
Summary for Patent: 9,907,849
Title: | Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer |
Abstract: | The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer. |
Inventor(s): | Petit; Robert (Newtown, PA), Mauro; David J. (Washington Crossing, PA), Perini; Rodolfo F. (North Wales, PA) |
Assignee: | Advaxis, Inc. (Princeton, NJ) Merck Sharp & Dohme Corp. (Rahway, NJ) |
Application Number: | 14/802,607 |
Patent Claims: | see list of patent claims |
Details for Patent 9,907,849
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2034-07-18 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2034-07-18 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |